GlassScriptPhysician profile
Mitchell Wells Jacocks
NPI 1881667897
$4,027.57
in general payments reported to CMS, 2019-2025
28 companies · $900 in 2025
The $900 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,099 · 2020: $265 · 2021: $309 · 2022: $628 · 2023: $376 · 2024: $451 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,289.70 | 2019-2025 | |
| Abbott Laboratories | $360.77 | 2019-2024 | Mitraclip |
| Amgen INC. | $331.74 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $269.17 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $203.66 | 2019-2025 | Farxiga, Wainua |
| Medtronic, INC. | $199.65 | 2021-2025 | Micra, Linq II, Cobalt Dr Mri Surescan |
| Merck Sharp & Dohme LLC | $181.16 | 2024-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $145.43 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $143.39 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $118.62 | 2024-2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $105.74 | 2024-2025 | Onpattro |
| Bridgebio Pharma, INC. | $91.77 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $82.17 | 2019 | |
| Philips North America LLC | $63.59 | 2024-2025 | (Ck4) Mcot, Holter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.96 | 2019-2024 | Lifevest |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $51.18 | 2024 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $47.85 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.47 | 2025 | |
| Biotronik INC. | $38.96 | 2019 | |
| Angiodynamics, INC. | $37.20 | 2025 | Alphavac |
| Boston Scientific Corporation | $30.01 | 2019 | |
| Stryker Corporation | $27.25 | 2025 | Clottriever Bold Catheter |
| Amarin Pharma, INC. | $26.65 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.86 | 2019 | |
| Esperion Therapeutics, INC. | $17.77 | 2025 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $15.32 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.27 | 2019 | |
| Gilead Sciences, INC. | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Jacocks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.